Telehealth psychiatric prescribing, the Ryan Haight Act, and cloud AI scribes: DEA investigation authority and the controlled substance documentation archive

The telehealth prescribing landscape in 2026

Telehealth psychiatric prescribing has expanded dramatically since the COVID-19 public health emergency waived the Ryan Haight Act's in-person examination requirement for telehealth controlled substance prescribing. At the peak of the PHE, prescribers across the country issued millions of controlled substance prescriptions — primarily stimulants for ADHD, benzodiazepines for anxiety disorders, and buprenorphine for opioid use disorder — to patients they had evaluated exclusively via video. Platforms including Cerebral, Done Health, and Talkiatry built large businesses on this model.

When the PHE ended, the DEA attempted to publish permanent telehealth prescribing rules and faced significant industry and patient pushback. The DEA's January 2023 Notice of Proposed Rulemaking would have restored much of the in-person evaluation requirement for Schedule II-III controlled substances with a narrow telehealth exception. The final regulatory framework that emerged — after multiple comment periods, withdrawn rules, and Congressional intervention — created a more permissive set of conditions for continued telehealth prescribing under DEA enforcement discretion and proposed special registration, with the long-term framework still being developed through rulemaking as of 2026.

What has not changed through any of these regulatory iterations is the DEA's investigative authority over prescribers. DEA administrative subpoena authority under 21 U.S.C. § 877 predates telehealth; it applies to all DEA registrants and to all third parties who hold records relevant to a registrant's controlled substance activities. The expansion of telehealth prescribing has created a corresponding expansion in DEA's enforcement interest — both in prescribers who were prescribing irresponsibly during the PHE and in prescribers operating in 2026 under the ongoing regulatory framework.

This is the context in which cloud AI scribes became widely adopted in telehealth psychiatric practice. Psychiatrists and psychiatric NPs conducting 30–50 medication management visits per day via telehealth have obvious efficiency reasons to adopt AI documentation assistance. The documentation compliance pressure of the Ryan Haight regime — requirements to document medical necessity and clinical judgment for each telehealth controlled substance prescription — makes AI-assisted documentation particularly appealing. What most prescribers have not thought through is what happens to the verbatim archive that cloud AI scribe vendors retain from those sessions.

For context on how cloud AI scribe documentation works in psychiatric medication management more generally, see our prior analysis of psychiatric medication management and cloud AI scribe data flows.

What a cloud AI scribe captures in telehealth controlled substance visits

A telehealth medication management visit for a patient receiving a stimulant, benzodiazepine, or other scheduled controlled substance produces session content that differs categorically from a psychotherapy session — and that is often more directly probative in a DEA investigation than any other documentation the prescriber creates.

Patient self-reported medication use. Patients routinely describe how they are actually taking their medication, which frequently diverges from the prescribed regimen. A patient on stimulants may describe taking doses strategically — holding doses for certain high-demand periods, skipping days, or doubling up before major deadlines. A patient on benzodiazepines may describe taking more than prescribed during anxiety spikes and less on calmer days. These self-reported patterns are normal clinical content; prescribers evaluate them in context. In a DEA investigation, a patient's verbatim account of how they are actually using their controlled substance prescription — captured in the vendor's archive — is direct evidence of whether the prescription was being used as prescribed and whether the prescriber's monitoring of that usage was adequate.

Co-occurring substance use disclosures. Patients in telehealth psychiatric medication management frequently disclose cannabis use, alcohol use, and recreational drug use that is clinically relevant to their treatment. A patient taking a stimulant and reporting cannabis use, or a patient on benzodiazepines who reports alcohol consumption, is disclosing information the prescriber must weigh in the prescribing decision. The prescriber's formal clinical note may summarize these disclosures as "patient reports occasional cannabis use, no other substances" — a clinically appropriate summary. The vendor's verbatim archive contains the patient's own description of the frequency, context, and combination with the prescribed medication. DEA investigators reviewing a case involving a patient who subsequently experienced an adverse event will find the gap between the formal note's summary and the verbatim disclosures directly relevant to their assessment of the prescriber's clinical judgment.

The prescriber's verbal prescribing rationale. During a telehealth prescribing session, the prescriber typically speaks their clinical reasoning aloud — both as part of the therapeutic interaction with the patient and as a dictation practice for note generation. "I'm going to continue you on your current dose of Adderall because your symptom control has been stable and you're reporting no side effects" is a statement that appears in many telehealth prescribing sessions. So is "Even though you're requesting an early refill, I don't see a clinical basis for increasing your dose — let's keep you at 20mg and check in next month." These spoken rationales are often more specific and less legally calibrated than what the prescriber includes in the formal note. DEA investigators reviewing verbatim session archives look specifically for spoken prescribing rationales that document either inadequate clinical basis for prescribing or evidence that the prescriber was aware of and ignored warning signs.

Diversion-relevant patient disclosures. Patients sometimes make statements in telehealth sessions that raise diversion concerns: reporting that they ran out of medication earlier than expected without a plausible explanation, describing sharing their medication with a family member, or requesting early refills for reasons the prescriber assessed as clinically benign but that sound different in a DEA investigation. The prescriber's formal note may document "patient denies medication diversion" — reflecting the prescriber's professional assessment after evaluating the patient's explanation. The vendor's verbatim archive captures what the patient actually said and how the prescriber responded, including any exchange in which the prescriber acknowledged a diversion-adjacent statement and continued prescribing.

Medication management decisions in real time. Prescribers sometimes make prescribing decisions during a session that reflect clinical judgment calls under uncertainty — deciding to continue a medication despite equivocal symptom control, accepting a patient's explanation for an early refill request, managing a patient who is requesting a dose increase the prescriber views as potentially appropriate but not clearly indicated. These real-time decision conversations are captured in the vendor's archive. They represent the actual clinical process behind each prescription decision — the unfiltered evidence of how the prescriber weighed competing considerations.

The gap between formal documentation and the vendor archive

DEA documentation requirements for controlled substance prescribing focus on the formal prescription record and the clinical note that supports it. Ryan Haight Act compliance documentation includes the basis for the telehealth prescribing decision, evidence that the in-person evaluation requirement was met or a valid exception applies, and the clinical necessity documentation for the specific prescription. These requirements shape how prescribers write their formal clinical notes.

What they do not shape is what the prescriber says aloud during the session, or what the patient says in response. The formal note reflects professional documentation judgment: what belongs in the legal medical record, what language is appropriate for a document that may be reviewed by DEA auditors, and what clinical content is relevant to the prescription decision. The vendor's verbatim archive reflects none of these professional documentation judgments. It is a complete transcript of everything said in the session — including everything the prescriber chose not to document because it was not clinically relevant, or because professional documentation standards called for a more measured characterization.

This gap is structurally identical to the gap in therapy documentation that we have analyzed in other contexts. The formal clinical note is what the clinician controls. The vendor archive is what a third party controls. In the controlled substance prescribing context, the gap is particularly significant because DEA investigators are specifically trained to look for discrepancies between what prescribers document and what prescribers do — and a verbatim session archive is the most direct available window into what actually happened in a prescribing visit.

For a broader analysis of how this formal-note-versus-vendor-archive gap operates in clinical documentation generally, see our analysis of what cloud AI scribes actually transmit and retain.

DEA investigation authority: what it reaches and how it works

The Drug Enforcement Administration's investigative authority over controlled substance prescribers is significantly broader than most healthcare regulatory authority — and it operates on a different timeline than the civil discovery process that characterizes most healthcare litigation.

21 U.S.C. § 877 administrative subpoena authority. Section 877 of the Controlled Substances Act authorizes the DEA Administrator to subpoena records or other documents "relevant or material to an investigation" of a DEA registrant's controlled substance activities. An administrative subpoena under § 877 is not a criminal warrant — it does not require probable cause and it does not require a judge's authorization. It is an administrative demand that the DEA can issue unilaterally in the course of a regulatory investigation, before any criminal charge is filed, and before the prescriber has been formally notified that they are under investigation.

A § 877 subpoena can be directed at anyone who holds relevant records, including third-party business records custodians. A cloud AI scribe vendor that holds the verbatim session archives of a prescriber's telehealth visits is a third-party custodian holding records directly relevant to that prescriber's controlled substance prescribing activities. The DEA can issue a § 877 subpoena to the vendor independently of any action taken against the prescriber.

HIPAA's law enforcement exception. HIPAA's law enforcement exception at 45 CFR § 164.512(f) permits a covered entity or business associate to disclose PHI in response to lawful process including administrative subpoenas and investigative demands from law enforcement. A DEA § 877 administrative subpoena is lawful process under this provision. The vendor may comply with the subpoena — producing the verbatim session archives of the prescriber's patients — without obtaining the prescriber's authorization or the patients' authorization. The DEA's investigative process may include a prohibition on the vendor disclosing the existence of the subpoena to the prescriber or the patients while the investigation is ongoing.

Federal grand jury subpoena authority. When a DEA investigation advances to a criminal referral, the federal grand jury has subpoena authority under Rule 17 of the Federal Rules of Criminal Procedure. A federal grand jury subpoena reaches any person or entity holding relevant records. The Stored Communications Act (18 U.S.C. § 2703) provides a parallel authority for electronic records held by service providers — it allows federal investigators to compel production of stored electronic communications and records from service providers through court orders and, in some circumstances, through grand jury subpoenas. A cloud AI scribe that stores session audio, transcripts, or derived records is a service provider holding stored content for purposes of the SCA. HIPAA's grand jury exception (45 CFR § 164.512(f)(1)(ii)(C)) permits the vendor to respond to a grand jury subpoena without the prescriber's authorization.

Five adversarial proceedings that reach the vendor archive

1. DEA administrative investigation under 21 U.S.C. § 877

The DEA routinely identifies telehealth prescribers for administrative investigation through prescription drug monitoring program (PDMP) data analysis, which flags prescribers with statistically elevated controlled substance prescription volumes or unusual prescribing patterns. A prescriber whose PDMP data triggers a DEA review becomes the subject of an investigation in which the DEA is gathering evidence about the prescriber's prescribing practices — specifically, whether each prescription was issued in the usual course of professional practice and for a legitimate medical purpose.

An administrative investigation under § 877 can result in a civil enforcement proceeding before a DEA administrative law judge — a proceeding that can suspend or revoke the prescriber's DEA registration without a criminal conviction. The standard of evidence in an administrative proceeding is lower than in a criminal trial. The vendor's verbatim archive of the prescriber's telehealth sessions is the most complete available evidence of what actually happened in each prescribing visit — more complete than the formal clinical note, and obtained by the DEA before the prescriber has an opportunity to review what the archive contains or to put its contents in clinical context.

Prescribers who receive notice of a DEA administrative investigation frequently do not know, at the time of notification, whether the DEA has already obtained their vendor's session archives through a § 877 subpoena. The investigation's factual record may have been substantially built before the prescriber is notified of the investigation's existence.

2. Federal criminal prosecution under 21 U.S.C. § 841

Section 841 of the Controlled Substances Act makes it a federal crime to knowingly or intentionally distribute or dispense a controlled substance "except as authorized" — with a specific provision under § 841(a) that a prescriber who issues a controlled substance prescription outside the usual course of professional practice or without a legitimate medical purpose is distributing a controlled substance as a matter of federal law. Prosecutions of prescribers under § 841 have been sustained by the Supreme Court in cases including Ruan v. United States (2022), which clarified that prosecutors must prove the prescriber subjectively knew they were acting outside legitimate practice standards.

In a federal criminal prosecution under § 841, the government's burden is to prove that the prescriber knew the prescriptions were not medically justified. A verbatim session archive that captures the prescriber's own spoken assessments — including sessions in which the prescriber acknowledged patient disclosures suggesting diversion risk and continued prescribing, or sessions in which the prescriber's spoken rationale differed materially from the formal clinical note — is powerful evidence on the subjective knowledge element. Federal grand jury subpoenas and SCA court orders give prosecutors access to the vendor's archive before trial. The prescriber may learn the content of their own session archives for the first time during trial preparation.

3. State medical or psychiatric licensing board investigation

State medical boards, psychiatric nursing boards, and advanced practice provider licensing boards investigate controlled substance prescribing complaints under the health oversight activities exception to HIPAA (45 CFR § 164.512(d)). Under this exception, a state licensing board — as a health oversight agency — can obtain PHI from covered entities and their business associates without patient authorization, in the course of investigating a licensee's professional conduct. Board administrative subpoenas reach cloud AI scribe vendors as business associates who hold PHI relevant to the prescribing practice under investigation.

A state licensing board investigation of a telehealth prescriber's controlled substance prescribing practices may issue a document request or administrative subpoena to the prescriber's cloud AI scribe vendor for verbatim records of all sessions involving the complainant patient, or — in pattern-of-practice investigations — for all sessions involving any patient to whom the prescriber issued a controlled substance prescription during a specific period. The board's investigative record may include a verbatim archive of dozens or hundreds of prescribing sessions before the prescriber is afforded an opportunity to review and respond to the evidence against them.

Unlike DEA administrative proceedings, state licensing board disciplinary actions result in the entry of a report to the National Practitioner Data Bank under 42 U.S.C. § 11131, which follows the prescriber through every subsequent credentialing action, hospital privilege application, and managed care panel enrollment for the remainder of their career.

4. State pharmacy board and PDMP investigation

State pharmacy boards have independent investigative authority over the dispensing of controlled substance prescriptions and over the prescribers whose prescriptions pharmacists dispense. In several states, pharmacy boards and the state PDMP administrator share investigative authority and can issue civil investigative demands to third parties — including clinical documentation vendors — as part of an inquiry into prescribing practices. A pharmacist who refuses to dispense a prescription and files a report with the state pharmacy board may trigger an investigation in which the board seeks clinical documentation of the prescriber's encounter with the patient. If the prescriber used a cloud AI scribe for that session, the pharmacy board's investigative demand may reach the vendor's archive of the session as a third-party record.

The intersection of PDMP data, pharmacy board authority, and cloud AI scribe vendor records creates a three-way documentation landscape that prescribers using cloud documentation tools have rarely analyzed. The PDMP holds dispensing data; the pharmacy holds the dispensed prescription record; the vendor holds the verbatim clinical encounter. Each is independently accessible to investigators through distinct but overlapping legal authority, and together they provide a more complete picture of the prescriber's practices than any single source alone.

5. Civil malpractice and wrongful death arising from prescribing

Controlled substance prescribing malpractice takes two forms that reach the vendor archive in opposite directions: overprescribing and underprescribing.

In overprescribing cases — where a patient is harmed or killed by a controlled substance prescribed via telehealth — the plaintiff's attorney seeks the vendor's verbatim session archive to compare against the formal clinical documentation. The formal note documents the prescriber's clinical necessity rationale and the patient's reported symptom status. The vendor archive captures everything the patient said and everything the prescriber said in response, including the unfiltered clinical exchange that formed the basis for the prescription decision. The liability theory in these cases often centers on the divergence between the formal note's measured language and what actually happened in the prescribing session — the patient's disclosures that the prescriber weighed and may have appropriately assessed but whose verbatim form reads very differently to a jury.

In underprescribing or abrupt discontinuation cases — where a patient is harmed by undertreated psychiatric symptoms or by abrupt discontinuation of a stimulant or benzodiazepine the prescriber stopped prescribing — the plaintiff seeks the sessions leading up to the discontinuation decision. The vendor archive of those sessions may capture the patient's requests for continued treatment, the prescriber's responses, and the clinical reasoning behind the discontinuation decision — content that is directly probative of whether the prescriber met the standard of care for managing a controlled substance discontinuation.

Civil discovery by Rule 45 subpoena reaches cloud AI scribe vendors as third-party records custodians. The subpoena can be served on the vendor without the prescriber's prior notice. For a broader analysis of how civil subpoenas reach cloud documentation vendors, see our analysis of whether AI therapy notes and scribe archives can be subpoenaed.

The Ryan Haight documentation problem in the vendor archive

The Ryan Haight Act creates a documentation requirement that is specifically designed to establish the medical legitimacy of a telehealth controlled substance prescription: the prescriber must be able to demonstrate, in the formal record, that the prescription was issued on the basis of a valid medical evaluation, that the patient's condition was assessed, and that the prescription was medically indicated. DEA auditors reviewing a prescriber's Ryan Haight compliance look at the formal clinical record to assess whether each prescription meets the statutory standard.

The vendor's verbatim session archive adds a second layer to this documentation picture — one the prescriber did not author, did not review before the DEA saw it, and did not calibrate to meet Ryan Haight documentation requirements. The formal note may document all the elements Ryan Haight compliance requires. The vendor archive may document a session in which the clinical exchange was more complicated than the formal note's summary suggests — a patient who was pressuring for a dose increase the prescriber declined, a patient who reported medication behaviors the prescriber assessed but whose verbatim description raises questions, or a prescriber who made prescribing decisions aloud that sound less defensible in transcript form than they did as clinical judgment calls in the moment.

The specific problem this creates in a DEA investigation is that the formal note and the vendor archive are now both available to investigators. The formal note represents the prescriber's professional documentation of a defensible clinical decision. The vendor archive is an unfiltered contemporaneous account that investigators can use to test the formal note's characterization of events. In any investigation where the question is whether the prescribing was legitimate, the vendor archive is the more powerful evidence — and it is held by a third party who has no obligation to the prescriber and limited incentive to resist a DEA administrative subpoena.

For context on the BAA framework that governs the vendor relationship and what it does and does not protect, see our analysis of what a business associate agreement covers and what it does not cover.

The telehealth platform investigation multiplier

Telehealth prescribers who work through platforms — Cerebral, Done Health, Talkiatry, and their competitors — face an additional dimension: when the platform itself comes under DEA scrutiny, all documentation associated with the platform's prescribers becomes relevant to the investigation. The high-profile federal investigations of Cerebral and Done Health in 2022–2023 for alleged controlled substance prescribing violations resulted in criminal charges against company executives, DEA show-cause orders against the company's registered prescribers, and broad document demands that reached the companies' records systems.

A prescriber who used a cloud AI scribe independently of their platform — a separate tool the prescriber adopted for their own documentation workflow, not the platform's official documentation system — has created a documentation trail that exists outside the platform's records management system. That trail may not have been within the scope of the platform's litigation hold or production to investigators. It exists as a separate archive at a third-party vendor, reachable through a separate § 877 subpoena or grand jury subpoena to the vendor.

In practice, this means that a platform prescriber who used a cloud AI scribe has created three independently subpoenable records: the platform's clinical and administrative records, the prescriber's own formal clinical documentation, and the vendor's verbatim session archives. Each is reachable through separate legal process. Together, they create a more complete evidentiary picture than any single source provides — and the most probative of the three, for DEA investigative purposes, is likely the vendor's verbatim session archive.

For a related analysis in the buprenorphine and opioid treatment program context, see our post on opioid treatment program documentation and AI scribes.

On-device processing: closing the vendor archive gap for prescribers

On-device processing eliminates the vendor archive that creates this exposure. When a prescriber's AI documentation assistance runs on a local device — session audio captured locally, transcription performed by a local model, draft documentation generated by a local model — no session audio, transcript, or derived content is transmitted to a cloud vendor. The vendor holds nothing and cannot be compelled to produce what it does not have.

For a telehealth psychiatric prescriber facing any of the five adversarial proceedings described above, the practical consequence is significant:

In a DEA § 877 administrative investigation, the subpoena can reach only the prescriber's own formal clinical records — documentation the prescriber created, reviewed, and maintained. The DEA still has access to PDMP dispensing data and pharmacy prescription records. What it cannot obtain through a third-party vendor subpoena is a verbatim archive of the prescriber's actual clinical sessions. The evidence base for the investigation is limited to sources the prescriber has had an opportunity to review and, through formal documentation practices, to calibrate against DEA standards.

In a federal criminal prosecution, the government's access to evidence of the prescriber's subjective clinical judgments is limited to what the prescriber's formal documentation captures and what patient testimony establishes. A verbatim session archive that might provide direct evidence of the prescriber's spoken assessments — including assessments that were clinically defensible but that sound concerning to a grand jury — does not exist as a separately held asset that prosecutors can subpoena from a third party.

In a state licensing board investigation, the board's document demand reaches the prescriber's formal records. On-device processing does not protect a prescriber whose formal records document inadequate care; it removes the second, separately held archive that provides a more granular picture of the prescribing sessions than the formal records contain.

In civil malpractice proceedings, Rule 45 discovery is limited to the prescriber's own records and to PDMP and pharmacy records. The plaintiff's attorney cannot serve a Rule 45 subpoena on a cloud vendor for session archives that do not exist at the vendor level.

On-device processing is not a protection against legitimate regulatory oversight. A prescriber whose prescribing practices are within the usual course of professional practice and who maintains complete, accurate formal clinical documentation is subject to the same regulatory framework regardless of their documentation tool. What on-device processing removes is the second, independently held verbatim record that a third party controls, that the prescriber has not reviewed, and that regulators and prosecutors can obtain before the prescriber knows they are under investigation.

Practical implications for psychiatric prescribers

Recognize that DEA investigation authority differs from typical civil discovery. Most prescribers understand that their formal clinical records could be subpoenaed in civil litigation. Fewer have considered that a § 877 administrative subpoena can reach a cloud AI scribe vendor's archives before a formal charge is filed, before the prescriber is notified of the investigation, and without a court's involvement. This is not a hypothetical risk in telehealth prescribing — DEA enforcement interest in telehealth controlled substance prescribing has been sustained and active since 2022, and the enforcement pattern involves broad document demands to platforms, prescribers, and associated vendors.

Map what your vendor actually holds. A prescriber who has used a cloud AI scribe for telehealth controlled substance prescribing for twelve months has, at a minimum, a twelve-month verbatim archive of every prescribing session retained at the vendor. That archive likely includes session audio, AI-generated transcripts, draft notes, and metadata about each session. The terms of service and the business associate agreement govern how long the vendor retains each category of data. Many vendors retain session content significantly longer than prescribers assume. Audit your vendor's retention policy and understand the scope of what is currently held.

Understand that a BAA does not protect vendor records from DEA subpoena. A BAA creates contractual obligations that require the vendor to maintain HIPAA compliance and to protect PHI against unauthorized disclosure. It does not override HIPAA's law enforcement exception. A DEA § 877 administrative subpoena is lawful process that the vendor may comply with under 45 CFR § 164.512(f) regardless of what the BAA says. Prescribers who believe the BAA protects their vendor's session archives from DEA process are mistaken about how the law enforcement exception interacts with business associate agreements.

Consider the documentation architecture appropriate for your prescribing context. Telehealth controlled substance prescribing is a higher-scrutiny regulatory activity than general outpatient mental health therapy. The same AI documentation tools that are appropriate for therapy note generation — where the documentation risk is primarily civil — create a different risk profile in controlled substance prescribing, where DEA administrative authority creates a pre-charge investigative regime that operates before the prescriber has an opportunity to review or respond to the evidence. Prescribers in this context should evaluate whether the documentation efficiency of a cloud AI scribe is worth the creation of a separately held, independently subpoenable verbatim archive of every controlled substance prescribing session.

Frequently asked questions

Can the DEA subpoena a cloud AI scribe vendor for a psychiatric prescriber's telehealth session records?

Yes. DEA administrative subpoena authority under 21 U.S.C. § 877 reaches any person holding records relevant to an investigation of a DEA registrant's controlled substance activities. A cloud AI scribe vendor that retains verbatim session archives from a prescriber's telehealth visits holds records that are directly relevant to any investigation of that prescriber's prescribing practices. The DEA can issue an administrative subpoena to the vendor as a separate third-party custodian, independently of any action against the prescriber, and HIPAA's law enforcement exception at 45 CFR § 164.512(f) permits the vendor to comply without the prescriber's authorization.

What does the Ryan Haight Act require telehealth prescribers to document?

The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 831) requires that prescribers conduct at least one in-person medical evaluation before prescribing controlled substances via telehealth, with DEA registration requirements and documentation of medical necessity for each prescription. The regulatory framework has evolved since COVID-19 — in 2026, prescribers should verify current DEA guidance for their specific prescribing context. The formal documentation the prescriber creates to meet Ryan Haight requirements exists separately from any cloud AI scribe vendor's verbatim session archive, and both are potentially reachable by DEA investigators.

How does a cloud AI scribe vendor's archive differ from the prescriber's formal clinical note in DEA investigations?

The formal clinical note reflects the prescriber's professional documentation judgment — what is clinically relevant, what language meets Ryan Haight documentation standards, and what characterization of the clinical encounter is appropriate for a legal medical record. The vendor's verbatim archive contains everything that was said in the session: the patient's self-reported medication use in their own words, co-occurring substance disclosures, the prescriber's spoken prescribing rationale in unfiltered form, and any diversion-adjacent statements the prescriber assessed clinically but that read differently to DEA investigators. DEA investigators specifically look for divergences between formal notes and verbatim session content — the gap between what the prescriber documented and what the prescriber did.

Does HIPAA prevent a cloud AI scribe vendor from responding to a DEA administrative subpoena?

No. HIPAA's law enforcement exception at 45 CFR § 164.512(f) permits a covered entity or business associate to disclose PHI in response to lawful process including DEA administrative subpoenas under 21 U.S.C. § 877. A business associate agreement requires the vendor to maintain HIPAA compliance but does not override the law enforcement exception. The vendor may comply with a DEA administrative subpoena by producing responsive PHI without the prescriber's authorization — and may be prohibited from notifying the prescriber of the subpoena while the investigation is ongoing.

Does on-device processing protect a telehealth psychiatric prescriber from DEA investigation?

On-device processing eliminates the separately subpoenable vendor archive. When AI inference runs on the prescriber's local device, no session content is held by a third-party vendor. DEA administrative subpoenas, grand jury subpoenas, and state licensing board demands are then limited to the prescriber's own formal records — documentation the prescriber controls and has reviewed. On-device processing does not protect a prescriber who is prescribing outside the usual course of professional practice; DEA can still investigate through PDMP data, pharmacy records, and the prescriber's formal documentation. What it removes is the second, independently held verbatim archive that a third party controls and that investigators can obtain before the prescriber knows an investigation has begun.